TY - JOUR A1 - Tony, Hans-Peter A1 - Burmester, Gerd A1 - Schulze-Koops, Hendrik A1 - Grunke, Mathias A1 - Henes, Joerg A1 - Kötter, Ina A1 - Haas, Judith A1 - Unger, Leonore A1 - Lovric, Svjetlana A1 - Haubitz, Marion A1 - Fischer-Betz, Rebecca A1 - Chehab, Gamal A1 - Rubbert-Roth, Andrea A1 - Specker, Christof A1 - Weinerth, Jutta A1 - Holle, Julia A1 - Müller-Ladner, Ulf A1 - König, Ramona A1 - Fiehn, Christoph A1 - Burgwinkel, Philip A1 - Budde, Klemens A1 - Sörensen, Helmut A1 - Meurer, Michael A1 - Aringer, Martin A1 - Kieseier, Bernd A1 - Erfurt-Berge, Cornelia A1 - Sticherling, Michael A1 - Veelken, Roland A1 - Ziemann, Ulf A1 - Strutz, Frank A1 - von Wussow, Praxis A1 - Meier, Florian MP A1 - Hunzelmann, Nico A1 - Schmidt, Enno A1 - Bergner, Raoul A1 - Schwarting, Andreas A1 - Eming, Rüdiger A1 - Schwarz-Eywill, Michael A1 - Wassenberg, Siegfried A1 - Fleck, Martin A1 - Metzler, Claudia A1 - Zettl, Uwe A1 - Westphal, Jens A1 - Heitmann, Stefan A1 - Herzog, Anna L. A1 - Wiendl, Heinz A1 - Jakob, Waltraud A1 - Schmidt, Elvira A1 - Freivogel, Klaus A1 - Dörner, Thomas A1 - Hertl, Michael A1 - Stadler, Rudolf T1 - Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID) JF - Arthritis Research & Therapy N2 - Introduction: Evidence from a number of open-label, uncontrolled studies has suggested that rituximab may benefit patients with autoimmune diseases who are refractory to standard-of-care. The objective of this study was to evaluate the safety and clinical outcomes of rituximab in several standard-of-care-refractory autoimmune diseases (within rheumatology, nephrology, dermatology and neurology) other than rheumatoid arthritis or non-Hodgkin’s lymphoma in a real-life clinical setting. Methods: Patients who received rituximab having shown an inadequate response to standard-of-care had their safety and clinical outcomes data retrospectively analysed as part of the German Registry of Autoimmune Diseases. The main outcome measures were safety and clinical response, as judged at the discretion of the investigators. Results: A total of 370 patients (299 patient-years) with various autoimmune diseases (23.0% with systemic lupus erythematosus, 15.7% antineutrophil cytoplasmic antibody-associated granulomatous vasculitides, 15.1% multiple sclerosis and 10.0% pemphigus) from 42 centres received a mean dose of 2,440 mg of rituximab over a median (range) of 194 (180 to 1,407) days. The overall rate of serious infections was 5.3 per 100 patient-years during rituximab therapy. Opportunistic infections were infrequent across the whole study population, and mostly occurred in patients with systemic lupus erythematosus. There were 11 deaths (3.0% of patients) after rituximab treatment (mean 11.6 months after first infusion, range 0.8 to 31.3 months), with most of the deaths caused by infections. Overall (n = 293), 13.3% of patients showed no response, 45.1% showed a partial response and 41.6% showed a complete response. Responses were also reflected by reduced use of glucocorticoids and various immunosuppressives during rituximab therapy and follow-up compared with before rituximab. Rituximab generally had a positive effect on patient well-being (physician’s visual analogue scale; mean improvement from baseline of 12.1 mm) KW - GRAID Y1 - 2011 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-142856 VL - 13 IS - R75 ER - TY - THES A1 - Meier, Michael T1 - Synthese und Eigenschaften von funktionalisierten Borolen und 1,2-Azaborininen T1 - Synthesis and properties of functionalized boroles and 1,2-azaborinines N2 - Im Rahmen dieser Arbeit konnte das Portfolio an literaturbekannten, freien Bisborolen beträchtlich erweitert werden. Die Reihe der Oligothiophen-verbrückten Borole konnte um die Vertreter der Ter- bzw. Quaterthiophene erweitert werden. Weiterhin wurden Lewisbasenaddukte mit IMes, CAAC und DMAP dargestellt und zur röntgenspektrographischen Charakterisierung herangezogen. Durch den Vergleich der spektroskopischen Daten mit den bereits literaturbekannten Vertretern wurde eine schrittweise Entwicklung der Absorptionsmaxima in Abhängigkeit der Anzahl der Thienyleinheiten detektiert. Daraus konnte sowohl auf eine Verkleinerung der HOMO-LUMO-Abstände mit zunehmender Kettenlänge, als auch die Entwicklung zu einem Grenzwert bei einer hypothetisch unendlichen Kettenlänge geschlossen werden, welcher sich bei ca. ca. 2,40 eV befindet. Weiterhin wurden 9,9-Dimethylfluoren und Biphenyl erfolgreich zu Bisborolen umgesetzt. Beide Systeme sind aufgrund ihrer strukturellen Gemeinsamkeiten sowie ihrer Vergleichbarkeit mit literaturbekannten Bis(borolyl)benzol - Verbindungen von besonderem Interesse. Zudem konnte ein Vergleich der spektroskopischen Daten aller literaturbekannten und im Rahmen dieser Arbeit dargestellten Bisborole bewerkstelligt werden. Es wurde somit gezeigt, dass heteroaromatisch-verbrückte Bisborole eine größere energetische HOMO-LUMO-Lücke aufzeigen, als aromatisch-verbrückte Systeme. Zudem spielt die Position der Borolylgruppen und der damit verbundene Grad an pi-Interaktionen eine wichtige Rolle. Die beiden im Rahmen dieser Arbeit dargestellten Systeme 1,1'-(9,9-Dimethylfluoren-2,7-diyl)bis-(2,3,4,5-tetraphenylborol) und 4,4'-Bis(2,3,4,5-tetraphenylborol-1-yl)-1,1'-biphenyl reihen sich energetisch zwischen dem 1,3- bzw. 1,4-Bis(2,3,4,5-tetraphenylborol-1-yl)benzol ein. Insbesondere der Vergleich zwischen 1,4-Bis(2,3,4,5-tetraphenylborol-1-yl)benzol und 4,4'-Bis(2,3,4,5-tetraphenylborol-1-yl)-1,1'-biphenyl offenbart keine signifikante Energiedifferenz zwischen einer Phenyl- und einer Biphenylbrücke, was ein Indiz dafür darstellt, dass die Erweiterung des Spacers um eine zweite Phenyleinheit bei analoger 1,4-Verknüpfung nahezu keinen Einfluss auf die elektronischen Eigenschaften des Systems hat. Auch die Überführung von 1,1'-(9,9-Dimethylfluoren-2,7-diyl)bis-(2,3,4,5-tetraphenylborol) und 4,4'-Bis(2,3,4,5-tetraphenylborol-1-yl)-1,1'-biphenyl in die entsprechenden 1,2-Azaborinine wurde unter Verwendung von Trimethylsilylazid bewerkstelligt. Neben der Darstellung und Untersuchung neuer Bisborole wurde 9-(Thiophen-2-yl)carbazol erfolgreich für den Aufbau borhaltiger Donor-Akzeptor-Systeme eingesetzt. Es konnten im Zuge dessen ein Borol und dessen IMes-Addukt, ein 1,2-Azaborinin sowie ein Dimesitylboryl-substituiertes Derivat dargestellt und auf ihre optischen und elektronischen Eigenschaften hin untersucht werden. Dabei stand insbesondere die elektrochemische Quantifizierung der Elektronenakzeptorstärke des Borols im Vergleich zum Dimesitylboran im Fokus. Es wurde ein signifikanter Unterschied des Borols (Epc = -1.60 V, CH2Cl2) im Vergleich zum Dimesitylboran (E1/2 = -2.39 V, THF) detektiert, woraus eine deutlich höhere Akzeptorstärke des Borols abgeleitet werden kann. Zusätzlich wurden spektroskopische und photophysikalische Untersuchungen in Abhängigkeit der jeweiligen Verbindung durchgeführt. Durch den Vergleich des energetisch niedrigsten Absorptionsmaximas des Borols mit bereits literaturbekannten, thienylsubstituierten Borolen konnte ein signifikanter Donoreinfluss der Carbazoleinheit bestätigt werden. N2 - Within the scope of this thesis, a library of novel, free bisborole compounds was prepared, characterized and their spectroscopic properties examined. Oligothiophen-bridged bisboroles could be extended to ter- and quaterthiophenes. Furthermore, Lewis base adducts with IMes, cAAC and DMAP were synthesized and characterized by X-ray crystallography. By comparing the spectroscopic data with literature-known compounds, a successive increase in the absorption maxima with the number of thiophene units could be observed/identified. Extension of the chain length leads to an increasingly smaller HOMO-LUMO gap and a limiting value of 2.40 eV considering a hypothetically infinitely long thiophene spacer. Furthermore, 9,9-dimethylfluorene and biphenyl were successfully converted into bisboroles. Both systems are of special interest due to their structural similarities and comparability to the literature-known Bis(borolyl)benzene - compounds. Additionally, a spectroscopic comparison between all new and literature-known bisboroles could be achieved during this work. It was shown that heteroaryl-brigded bisboroles offer a larger HOMO-LUMO gap then aryl-brigded systems. Furthermore the position of the borolyl groups and the degree of pi-conjugation play an important role. Both systems 1,1'-(9,9-dimethylfluorene-2,7-diyl)bis-(2,3,4,5-tetraphenylborole) and 4,4'-bis(2,3,4,5-tetraphenylborole-1-yl)-1,1'-biphenyl are found to be energetically between 1,3- and 1,4-bis(2,3,4,5-tetraphenylborole-1-yl)benzene. The comparison between 1,4-bis(2,3,4,5-tetraphenylborole-1-yl)benzene and 4,4'-bis(2,3,4,5-tetraphenylborole-1-yl)-1,1'-biphenyl shows almost no difference in energy between a phenyl- and biphenyl-bridged system, indicating that expanding the system with another phenyl unit with the same 1,4-linkage has virtually no influence on the electronic properties. Additionally, the conversion of 1,1'-(9,9-dimethylfluorene-2,7-diyl)bis-(2,3,4,5-tetraphenylborole) and 4,4'-bis(2,3,4,5-tetraphenylborole-1-yl)-1,1'-biphenyl into the corresponding 1,2-azaborinines was achieved by reaction with trimethylsilyl azide. Besides the synthesis and investigation of new bisborole compounds, 9-(thiophen-2-yl)carbazole was successfully converted into new donor-acceptor-systems. Based on this system, a borole, an IMes-adduct, an 1,2-azaborinine and also a dimesitylboryl-substituted derivative were successfully prepared, characterized and investigated for their optical and electronic properties, with focus on the electrochemical quantification of the Lewis acid strength of the borole and the dimesitylborane. A significant difference in the first reduction potentials was detected between the borole (Epc = 1.60 V, CH2Cl2) and the dimesitylborane (E1/2 = -2.39 V, THF), indicating a much higher acceptor strength of borole. Additionally, spectroscopic and photophysical investigations were performed on each of these compounds. By comparison of the lowest maximum of the borole with literature-known, thienyl-substituted boroles, a significant donor influence of the carbazole group could be confirmed. KW - Borheterocyclen KW - Fünfringheterocyclen KW - Lewis-Säure KW - Sechsringverbindungen KW - Aromatische Verbindungen KW - Borole KW - 1,2-Azaborinine KW - Donor-Brücke-Akzeptor Systeme KW - Bisborole KW - Thiophen KW - boroles KW - 1,2-azaborinines KW - donor–bridge–acceptor systems KW - bisboroles KW - thiophene Y1 - 2020 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-178402 ER - TY - JOUR A1 - Koch, Elias A. T. A1 - Petzold, Anne A1 - Wessely, Anja A1 - Dippel, Edgar A1 - Gesierich, Anja A1 - Gutzmer, Ralf A1 - Hassel, Jessica C. A1 - Haferkamp, Sebastian A1 - Hohberger, Bettina A1 - Kähler, Katharina C. A1 - Knorr, Harald A1 - Kreuzberg, Nicole A1 - Leiter, Ulrike A1 - Loquai, Carmen A1 - Meier, Friedegund A1 - Meissner, Markus A1 - Mohr, Peter A1 - Pföhler, Claudia A1 - Rahimi, Farnaz A1 - Schadendorf, Dirk A1 - Schell, Beatrice A1 - Schlaak, Max A1 - Terheyden, Patrick A1 - Thoms, Kai-Martin A1 - Schuler-Thurner, Beatrice A1 - Ugurel, Selma A1 - Ulrich, Jens A1 - Utikal, Jochen A1 - Weichenthal, Michael A1 - Ziller, Fabian A1 - Berking, Carola A1 - Heppt, Markus T1 - Immune checkpoint blockade for metastatic uveal melanoma: patterns of response and survival according to the presence of hepatic and extrahepatic metastasis JF - Cancers N2 - Background: Since there is no standardized and effective treatment for advanced uveal melanoma (UM), the prognosis is dismal once metastases develop. Due to the availability of immune checkpoint blockade (ICB) in the real-world setting, the prognosis of metastatic UM has improved. However, it is unclear how the presence of hepatic and extrahepatic metastasis impacts the response and survival after ICB. Methods: A total of 178 patients with metastatic UM treated with ICB were included in this analysis. Patients were recruited from German skin cancer centers and the German national skin cancer registry (ADOReg). To investigate the impact of hepatic metastasis, two cohorts were compared: patients with liver metastasis only (cohort A, n = 55) versus those with both liver and extra-hepatic metastasis (cohort B, n = 123). Data were analyzed in both cohorts for response to treatment, progression-free survival (PFS), and overall survival (OS). The survival and progression probabilities were calculated with the Kaplan–Meier method. Log-rank tests, χ\(^2\) tests, and t-tests were performed to detect significant differences between both cohorts. Results: The median OS of the overall population was 16 months (95% CI 13.4–23.7) and the median PFS, 2.8 months (95% CI 2.5–3.0). The median OS was longer in cohort B than in cohort A (18.2 vs. 6.1 months; p = 0.071). The best objective response rate to dual ICB was 13.8% and to anti-PD-1 monotherapy 8.9% in the entire population. Patients with liver metastases only had a lower response to dual ICB, yet without significance (cohort A 8.7% vs. cohort B 16.7%; p = 0.45). Adverse events (AE) occurred in 41.6%. Severe AE were observed in 26.3% and evenly distributed between both cohorts. Conclusion: The survival of this large cohort of patients with advanced UM was more favorable than reported in previous benchmark studies. Patients with both hepatic and extrahepatic metastasis showed more favorable survival and higher response to dual ICB than those with hepatic metastasis only. KW - uveal melanoma KW - immune checkpoint blockade KW - PD-1 KW - CTLA-4 KW - liver metastasis KW - treatment resistance Y1 - 2021 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-242603 SN - 2072-6694 VL - 13 IS - 13 ER - TY - JOUR A1 - Lodde, Georg A1 - Forschner, Andrea A1 - Hassel, Jessica A1 - Wulfken, Lena M. A1 - Meier, Friedegund A1 - Mohr, Peter A1 - Kähler, Katharina A1 - Schilling, Bastian A1 - Loquai, Carmen A1 - Berking, Carola A1 - Hüning, Svea A1 - Schatton, Kerstin A1 - Gebhardt, Christoffer A1 - Eckardt, Julia A1 - Gutzmer, Ralf A1 - Reinhardt, Lydia A1 - Glutsch, Valerie A1 - Nikfarjam, Ulrike A1 - Erdmann, Michael A1 - Stang, Andreas A1 - Kowall, Bernd A1 - Roesch, Alexander A1 - Ugurel, Selma A1 - Zimmer, Lisa A1 - Schadendorf, Dirk A1 - Livingstone, Elisabeth T1 - Factors influencing the adjuvant therapy decision: results of a real-world multicenter data analysis of 904 melanoma patients JF - Cancers N2 - Adjuvant treatment of melanoma patients with immune-checkpoint inhibition (ICI) and targeted therapy (TT) significantly improved recurrence-free survival. This study investigates the real-world situation of 904 patients from 13 German skin cancer centers with an indication for adjuvant treatment since the approval of adjuvant ICI and TT. From adjusted log-binomial regression models, we estimated relative risks for associations between various influence factors and treatment decisions (adjuvant therapy yes/no, TT vs. ICI in BRAF mutant patients). Of these patients, 76.9% (95% CI 74–80) opted for a systemic adjuvant treatment. The probability of starting an adjuvant treatment was 26% lower in patients >65 years (RR 0.74, 95% CI 68–80). The most common reasons against adjuvant treatment given by patients were age (29.4%, 95% CI 24–38), and fear of adverse events (21.1%, 95% CI 16–28) and impaired quality of life (11.9%, 95% CI 7–16). Of all BRAF-mutated patients who opted for adjuvant treatment, 52.9% (95% CI 47–59) decided for ICI. Treatment decision for TT or ICI was barely associated with age, gender and tumor stage, but with comorbidities and affiliated center. Shortly after their approval, adjuvant treatments have been well accepted by physicians and patients. Age plays a decisive role in the decision for adjuvant treatment, while pre-existing autoimmune disease and regional differences influence the choice between TT or ICI. KW - melanoma KW - adjuvant treatment KW - checkpoint blocker KW - targeted therapy KW - BRAF KW - PD-1 Y1 - 2021 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-239583 SN - 2072-6694 VL - 13 IS - 10 ER - TY - JOUR A1 - Koch, Elias A. T. A1 - Petzold, Anne A1 - Wessely, Anja A1 - Dippel, Edgar A1 - Gesierich, Anja A1 - Gutzmer, Ralf A1 - Hassel, Jessica C. A1 - Haferkamp, Sebastian A1 - Kähler, Katharina C. A1 - Knorr, Harald A1 - Kreuzberg, Nicole A1 - Leiter, Ulrike A1 - Loquai, Carmen A1 - Meier, Friedegund A1 - Meissner, Markus A1 - Mohr, Peter A1 - Pföhler, Claudia A1 - Rahimi, Farnaz A1 - Schadendorf, Dirk A1 - Schell, Beatrice A1 - Schlaak, Max A1 - Terheyden, Patrick A1 - Thoms, Kai-Martin A1 - Schuler-Thurner, Beatrice A1 - Ugurel, Selma A1 - Ulrich, Jens A1 - Utikal, Jochen A1 - Weichenthal, Michael A1 - Ziller, Fabian A1 - Berking, Carola A1 - Heppt, Markus V. T1 - Immune checkpoint blockade for metastatic uveal melanoma: re-induction following resistance or toxicity JF - Cancers N2 - Re-induction with immune checkpoint blockade (ICB) needs to be considered in many patients with uveal melanoma (UM) due to limited systemic treatment options. Here, we provide hitherto the first analysis of ICB re-induction in UM. A total of 177 patients with metastatic UM treated with ICB were included from German skin cancer centers and the German national skin cancer registry (ADOReg). To investigate the impact of ICB re-induction, two cohorts were compared: patients who received at least one ICB re-induction (cohort A, n = 52) versus those who received only one treatment line of ICB (cohort B, n = 125). In cohort A, a transient benefit of overall survival (OS) was observed at 6 and 12 months after the treatment start of ICB. There was no significant difference in OS between both groups (p = 0.1) with a median OS of 16.2 months (cohort A, 95% CI: 11.1–23.8) versus 9.4 months (cohort B, 95% CI: 6.1–14.9). Patients receiving re-induction of ICB (cohort A) had similar response rates compared to those receiving ICB once. Re-induction of ICB may yield a clinical benefit for a small subgroup of patients even after resistance or development of toxicities. KW - uveal melanoma KW - immune checkpoint blockade KW - PD-1 KW - CTLA-4 KW - re-induction KW - treatment resistance KW - toxicity Y1 - 2022 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-254814 SN - 2072-6694 VL - 14 IS - 3 ER - TY - JOUR A1 - Meier, Doreen A1 - Kruse, Janis A1 - Buttlar, Jann A1 - Friedrich, Michael A1 - Zenk, Fides A1 - Boesler, Benjamin A1 - Forstner, Konrad U. A1 - Hammann, Christian A1 - Nellen, Wolfgang T1 - Analysis of the Microprocessor in Dictyostelium: The Role of RbdB, a dsRNA Binding Protein JF - PLoS Genetics N2 - We identified the dsRNA binding protein RbdB as an essential component in miRNA processing in Dictyostelium discoideum. RbdB is a nuclear protein that accumulates, together with Dicer B, in nucleolar foci reminiscent of plant dicing bodies. Disruption of rbdB results in loss of miRNAs and accumulation of primary miRNAs. The phenotype can be rescued by ectopic expression of RbdB thus allowing for a detailed analysis of domain function. The lack of cytoplasmic dsRBD proteins involved in miRNA processing, suggests that both processing steps take place in the nucleus thus resembling the plant pathway. However, we also find features e.g. in the domain structure of Dicer which suggest similarities to animals. Reduction of miRNAs in the rbdB- strain and their increase in the Argonaute A knock out allowed the definition of new miRNAs one of which appears to belong to a new non-canonical class. KW - microprocessor KW - Dictyostelium discoideum KW - dsRNA binding protein KW - RbdB Y1 - 2016 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-166687 VL - 12 IS - 6 ER - TY - JOUR A1 - Hecht, Markus A1 - Meier, Friedegund A1 - Zimmer, Lisa A1 - Polat, Bülent A1 - Loquai, Carmen A1 - Weishaupt, Carsten A1 - Forschner, Andrea A1 - Gutzmer, Ralf A1 - Utikal, Jochen S. A1 - Goldinger, Simone M. A1 - Geier, Michael A1 - Hassel, Jessica C. A1 - Balermpas, Panagiotis A1 - Kiecker, Felix A1 - Rauschenberg, Ricarda A1 - Dietrich, Ursula A1 - Clemens, Patrick A1 - Berking, Carola A1 - Grabenbauer, Gerhard A1 - Schadendorf, Dirk A1 - Grabbe, Stephan A1 - Schuler, Gerold A1 - Fietkau, Rainer A1 - Distel, Luitpold V. A1 - Heinzerling, Lucie T1 - Clinical outcome of concomitant vs interrupted BRAF inhibitor therapy during radiotherapy in melanoma patients JF - British Journal of Cancer N2 - Background: Concomitant radiation with BRAF inhibitor (BRAFi) therapy may increase radiation-induced side effects but also potentially improve tumour control in melanoma patients. Methods: A total of 155 patients with BRAF-mutated melanoma from 17 European skin cancer centres were retrospectively analysed. Out of these, 87 patients received concomitant radiotherapy and BRAFi (59 vemurafenib, 28 dabrafenib), while in 68 patients BRAFi therapy was interrupted during radiation (51 vemurafenib, 17 dabrafenib). Overall survival was calculated from the first radiation (OSRT) and from start of BRAFi therapy (OSBRAFi). Results: The median duration of BRAFi treatment interruption prior to radiotherapy was 4 days and lasted for 17 days. Median OSRT and OSBRAFi in the entire cohort were 9.8 and 12.6 months in the interrupted group and 7.3 and 11.5 months in the concomitant group (P=0.075/P=0.217), respectively. Interrupted vemurafenib treatment with a median OSRT and OSBRAFi of 10.1 and 13.1 months, respectively, was superior to concomitant vemurafenib treatment with a median OSRT and OSBRAFi of 6.6 and 10.9 months (P=0.004/P=0.067). Interrupted dabrafenib treatment with a median OSRT and OSBRAFi of 7.7 and 9.8 months, respectively, did not differ from concomitant dabrafenib treatment with a median OSRT and OSBRAFi of 9.9 and 11.6 months (P=0.132/P=0.404). Median local control of the irradiated area did not differ in the interrupted and concomitant BRAFi treatment groups (P=0.619). Skin toxicity of grade ≥2 (CTCAE) was significantly increased in patients with concomitant vemurafenib compared to the group with treatment interruption (P=0.002). Conclusions: Interruption of vemurafenib treatment during radiation was associated with better survival and less toxicity compared to concomitant treatment. Due to lower number of patients, the relevance of treatment interruption in dabrafenib treated patients should be further investigated. The results of this analysis indicate that treatment with the BRAFi vemurafenib should be interrupted during radiotherapy. Prospective studies are desperately needed. KW - radiation KW - radiotherapy KW - BRAF KW - vemurafenib KW - dabrafenib Y1 - 2018 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-227970 VL - 118 ER -